close

Enter

Log in using OpenID

Peptide-Based Gastrointestinal Disorders Therapeutics Market

embed
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptide-based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders.
Peptide-Based Gastrointestinal Disorders Therapeutics
Market - Size, Share, Outlook, and Opportunity Analysis,
2018 – 2026
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptidebased gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of
various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel
syndrome. In the recent past, some peptide-based therapeutics such as Trulance, Linaclotide,
and Teduglutide received approval for the treatment of GIT disorders.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2028
Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic
constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of
guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate
cyclase C receptors in the intestine and is used for the treatment of chronic constipation and
irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide
(GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal
tract.
Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics
Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in
key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics
market growth over the forecast period.
For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug
Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug
is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food
and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is
a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel
syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
In 2016, Ironwood Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing
approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and
in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan.
In 2012, NPS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug
Administration (FDA) for its drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d
injection is a new, recombinant analog of human glucagon-like peptide 2, a protein involved in
the rehabilitation of the intestinal lining. It is indicated for the treatment of adult patients with
short bowel syndrome (SBS) who are dependent on parenteral support. Sucg frequent approval
is expected to cather peptide-based gastrointestinal disorders therapeutics market growth in near
future.
Report includes chapters which deeply display the following deliverable about industry :
• Peptide-Based Gastrointestinal Disorders Therapeutics Market Research Objective and
Assumption
• Peptide-Based Gastrointestinal Disorders Therapeutics Market Purview - Report Description,
Executive Summary, and Coherent Opportunity Map (COM)
• Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics, Regulations, and
Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and
Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST
Analysis
• Global Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Regions
• Peptide-Based Gastrointestinal Disorders Therapeutics Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales
Area and Product Type.
• Peptide-Based Gastrointestinal Disorders Therapeutics Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Peptide-Based Gastrointestinal Disorders Therapeutics Market Manufacturing Cost Analysis
including Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Peptide-Based Gastrointestinal Disorders Therapeutics Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis
North America peptide-based gastrointestinal disorders therapeutics market is expected to exhibit
good growth over the forecast period, owing to presence of major players and adoption of
strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For
instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of
the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy
Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market,
distribute, and sell Trulance (plecanatide) in the Canadian Market.
Browse Report For More Information @ https://www.coherentmarketinsights.com/ongoinginsight/peptide-based-gastrointestinal-disorders-therapeutics-market-2028
Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit
significant growth over the forecast period, owing to increasing investments made by players in
the region to receive approval of novel peptide-based therapeutics. For instance, in 2014,
Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japanbased pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in
Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016.
Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under strategic partnership since
2009 for developing and commercializing linaclotide in Japan.
Peptide-Based Gastrointestinal Disorders Therapeutics Market Key Players
Key players operating in the global peptide-based gastrointestinal disorders therapeutics market
include Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy Pharmaceuticals
Inc., Astellas Pharma Inc., Allergan plc., and Cipher Pharmaceuticals Inc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
1/--pages
Report inappropriate content